Novel game-changing method to generate cell-friendly microfluidic devices on demand

Jet-printing microfluidic devices on demand – a new paper from engineering and biomedical scientists at the University of Oxford and spin-out company iotaSciences Ltd – describes a game-changing method to generate cell-friendly microfluidic devices on demand.

This innovative protocol offers significant benefits to biology and biomedicine, enabling simple, contactless fabrication of microfluidic circuits in minutes – almost as quickly as the circuit pattern can be drawn on paper – using truly cell-friendly materials; standard Petri dishes and culture media.

Novel game-changing method to generate cell-friendly microfluidic devices on demand
Walls made of a clear immiscible liquid, fabricated by jetting, confine red and blue dyes filling the ‘arteries’ and ‘veins’.

The pioneering jet-printing method stems from the recognition that gravity becomes irrelevant at the microscale. In the everyday world, objects are invariably made with solids; building complex structures out of liquids, which would collapse into puddles and drain away, is not feasible.

Using microjets to fabricate microfluidic devices takes advantage of the interfacial forces that dominate in the microworld. In this paper, the method was used to successfully clone cells by limiting dilution in a way that beats the Poisson limit, to subculture adherent cells, and to feed arrays of cells continuously for a week in sub-microliter chambers. Liquid flows were driven through conduits with and without external pumps, and circuits reconfigured to open and close ‘fluidic valves’ at will. The diversity and flexibility of this approach is expected to lead to widespread adoption of the technique for a variety of applications in biomedicine.

This open access paper was published on the 26th of October and is available to download at https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202001854

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First U.S. trial uses non-viral CRISPR to correct sickle cell mutation